APAC Ligation Devices Market: Volume Growth, Price Compression and Procurement Reform in Asia-Pacific

Executive Summary

The Asia-Pacific (APAC) ligation devices market is projected to reach USD 1,210 million by 2035, a CAGR of 7.45%. Unit volumes grow faster, at 9.76% a year to 158.3 million pieces in 2026, because the realised price per device keeps falling. More operations, not higher prices, are driving the market.

Demand rests on surgical caseload. Ligation clips, clip appliers, band ligators and vessel ligation systems are consumed by the operation, so rising inpatient admissions, wider adoption of minimally invasive surgery and growing healthcare spending in emerging economies all lift volumes. At the same time, China's February 2025 volume-based procurement (VBP) cut winning clip prices by an average of 59.83%, and local manufacturers are intensifying price pressure across the region.

Introduction

Ligation devices occlude vessels, ducts and tissue structures during surgical and endoscopic procedures. The category covers ligation clips (titanium, polymer and absorbable), clip appliers, ligation loop and band ligation devices, and vessel ligation systems. A clip is an implant: it stays in the body once the wound closes, which places it in the highest-control device classes in China, Japan and most other markets.

The study covers 14 named countries, China, Japan, India, South Korea, Australia, New Zealand, Singapore, Thailand, Indonesia, Malaysia, Vietnam, the Philippines, Taiwan and Hong Kong, plus Rest of Asia-Pacific. Figures are measured at manufacturer revenue, not hospital expenditure, which matters because most of China's 2025 price cut fell on distribution margin rather than factory price. Energy-based vessel sealing, sutures, staplers and endoscopic haemostasis clips are outside the scope.

Key Factors Driving Demand for Ligation Devices in APAC

Several structural trends support the expansion of the market

•  Growing Surgery Volumes

A ligation device is consumed by the operation, not the patient. A laparoscopic cholecystectomy retires eight to ten clips that must be bought again for the next case. China's hospitals admitted 254.62 million inpatients in 2024, up 3.3% on 2023 (National Health Commission), and South Korea was performing 149 cholecystectomies per 100,000 people as early as 2018, growing 5.9% a year. General surgery is the largest procedure group at USD 181.80 million in 2026.

• Shift to Minimally Invasive and Robotic Surgery

Minimally invasive surgery is worth USD 342.03 million in 2026 and grows 7.76% a year. Robotic-assisted surgery is the fastest-growing approach at 12.82%, although it is still small at about USD 37 million. Australia already performs 96% of cholecystectomies laparoscopically against an OECD average of 90%, according to the Australian Institute of Health and Welfare.

• Rising Treatment Rates in Emerging Market

Minimally invasive surgery is worth USD 342.03 million in 2026 and grows 7.76% a year. Robotic-assisted surgery is the fastest-growing approach at 12.82%, although it is still small at about USD 37 million. Australia already performs 96% of cholecystectomies laparoscopically against an OECD average of 90%, according to the Australian Institute of Health and Welfare. Lower-income markets treat a smaller share of the same disease burden, and treat more of it by open surgery. As that changes, India is expected to grow 10.21% a year against 5.11% for Japan. Rising healthcare expenditure in emerging APAC countries adds to this pull.

• Product Innovation

Absorbable clips grow 9.11% a year, and rotatable-jaw appliers and combined clip-and-applier systems grow 8.16% and 8.24%. All outpace the overall market because each removes a specific nuisance, such as migration, imaging artefact or an instrument exchange.

Procedure Burden Supporting Market Growth

Because a ligation device treats no disease of its own, demand follows the conditions that lead to surgery: gallstone disease, appendicitis, gynaecological disease, renal and prostatic tumours, colorectal cancer and portal hypertension. The last is the most regionally distinctive. Oesophageal variceal bleeding, driven by viral hepatitis and cirrhosis, sustains band ligation demand in the largest countries, and endoscopic procedures are the fastest-growing of the ten procedure groups at 8.17% a year.

Estimated Procedure Groups Driving Ligation Device Demand in APAC, 2026

Source: DBMR Analysis

Regulation and Reimbursement: How a Ligation Clip Reaches the Market

Twelve markets are governed by twelve regulators, and no approval is recognised by another. A supplier selling one clip across the region holds a separate registration in each country, maintained, renewed and inspected separately. This is the largest non-manufacturing cost in the market and a main reason many small suppliers stay local or sell through distributors.

Pricing Benchmark

Price is set by what the device has to hold and by who is buying it. Material, format and country explain most of the spread, and tender exposure is the largest single influence. Within each country, realised price falls roughly 9.5% across the forecast. Regionally it falls further, by 14.1%, because China and India take a growing share of units at below-average prices. Plan against the country price, not the regional average.

APAC Ligation Devices Pricing Benchmark

Comparison of Emerging Ligation Technologies

Business Opportunities Across the APAC Ligation Devices Ecosystem

The largest segments are the ones a national tender has already reached, and the fastest-growing ones are small. China is about 47% of the region at USD 296.51 million in 2026, growing 7.83% a year, but single-fire clips there can now be sold only at tendered prices. India is the fastest-growing large market at 10.21% a year from USD 33.94 million, with the lowest prices. Japan, at USD 112.51 million, grows only 5.11% but supports premium formats. South Korea (USD 47.23 million) and Australia (USD 42.55 million) are mature and grow by format rather than caseload.

Clip appliers grow faster than clips, at 7.73% against 7.16%, because an applier supplied with its cartridge is judged as an instrument. Moving customers from single-fire clips to multi-fire appliers and combined systems lifts revenue per case several times over, and only twenty firms won places in China's multi-fire bidding unit. Absorbable and polymer clips are won on design and patents rather than plant scale, so specialists can hold defensible positions without competing on cost.

Competitive Landscape

The global market exhibits a highly fragmented competitive structure, with no supplier accounting for more than 6.2% of the market in 2025. Johnson & Johnson (Ethicon) led the market with a 6.2% share, followed by Medtronic (Covidien) at 5.4%, Hangzhou Kangji Medical at 5.1%, Teleflex at 4.6%, Boston Scientific at 4.3%, and Olympus at 4.1%. While multinational companies maintain leading positions in terms of market value, Asia-Pacific manufacturers are gradually strengthening their competitive presence. In China, 91 enterprises secured positions in the 2024 clip tender, with Teleflex emerging as the largest single-fire winner.

Future Outlook: Where Is Alberta's Custom Orthotics Market Heading?

The market is expected to keep growing steadily, with unit demand outrunning value in every forecast year. Rising surgical caseload, higher treatment rates in India and South-East Asia, and the slow conversion from open to minimally invasive surgery will sustain volume. Price per device will continue to slip, so growth will depend on mix: formats, materials and countries.

The main risk to volume is a health-system shock, such as the elective surgery suspensions of 2020 and 2022, rather than a competitor. The main commercial risk is that procurement reform spreads. China's tender mechanism is cheap for a government to run and its documents are public, so a second ministry adopting it is a question of timing.

Emerging Trends Shaping the Market

• Spread of Volume-Based Procurement
• Migration to Multi-Fire Appliers and Combined Systems
• Absorbable and Polymer Clip Adoption
• Growth of Robotic-Assisted Surgery
• Supplier-Funded Surgeon Training

Conclusion

The APAC ligation devices market is well positioned for sustained growth, expanding from USD 634 million in 2026 to USD 1,210 million by 2035. Surgical volumes, minimally invasive and robotic adoption, and rising healthcare spending in emerging markets support demand, while regulation, procurement reform and local competition keep prices under pressure.

In a fragmented market where no supplier holds more than 6.2%, success will go to companies that compete where a tender cannot reach: multi-fire and combined systems, absorbable and polymer materials, and training-led adoption. Hospitals and payers should expect volumes to rise and unit prices to keep falling, and should plan against country-level prices rather than a regional average.